CDX (ASX) Mobvoi

Originally posted by Quiltman: ↑

Too excited not to pop back into the dark side for a moment given the long awaited launch is with us. Congrats to all LTH to what has been a pretty miserable few quarters. This is a little summary I posted elsewhere for the journey so far for any newbies looking in :

Mobvoi will be launching a smartwatch featuring a set of CardieX Health parameters and an associated heart health ecosystem on March 1st. This will be a major milestone for CardieX, moving it's central blood pressure know how from hospitals, labs and clinical trials ( where it's success continues to grow ) into the hands of consumers. While CardieX are working on it's own, FDA cleared consumer devices through the ConneQt division for launch later in 2022, this launch with Mobvoi will be an important step in the CardieX journey towards owning vascular health.

LTH's such as myself had become impatient waiting for the launch as it has been delayed from timelines originally communicated, but to be honest what hasn't been delayed through Covid delays and delays with chips etc. So for anyone who is interested, here is a bit of a chronological snapshot of this co-development between Mobvoi & CardieX

..........................................................

Who is Mobvoi

Mobvoi is Googles official partner in China , known for it's TicWatch range, is one of the worlds largest sellers of smartwatches and wearables. It's major investors include Google & Volkswagen.

11/9/2019 - CardieX announces JV with Mobvoi

Co development of consumer health application on Mobvoi line of smartwatches and wearables.
commercial execution to be through Atcor, a CardieX subsidiary.
Atcor responsible for developing set of algorithms & features for implementation in Mobvoi smartwatches and accompanying apps to form smart heart health ecosystem.
Mobvoi to develop next generation smartwatch to intergrate the above.
29/1/2020 - Cardiex Engages MEDL Mobile for App Saas & Cloud Development

development & design of features and applications to be incorporated into the Mobvoi smartwatch.
24/4/2020 - CardieX completes major milestone in development of sensor technology
CardieX announced they can extract a waveform from a ppg sensor that is equivalent to a Sphygmocor derived waveform, a game changing development.
24/9/2020 - Commercial Partnership with Mobvoi for new Heart Health smartwatches announced

agreement to launch a new line of smartwatches with heart and arterial health management features. It will feature Atcor Heart Stress, Arterial Age, Exercise Capacity and Arty Score, plus AI powered health coaching services.
Revenues to CardieX from subscription fees for app premium services, product sale revenues on direct to consumer sales and shared distribution rights.
Mobvoi to guarantee MOQ's for first 2 years after FULL market launch.
Initial market launch 6 months across US & Australia.

Through2021, the development of the watch has progressed, with an expectation of launch in 2021. For reasons only known to Mobvoi, this has extended to initial launch in 1st Quarter, 2022.

Both CardieX and Mobvoi have employed the services of new PR companies and advertising specialists to jointly develop launch strategies over the last 6 months.

We are now in the final throes of preparation for the initial launch phase in US & Aust.

A joint statement was made in October 2021 :

NEWPORT BEACH, Calif. and SYDNEY, Australia, Oct. 19, 2021 (GLOBE NEWSWIRE) -- CardieX (CardieX, the Company) and Mobvoi are excited to announce significant progress towards commercialization and launch of a new smartwatch with first-in-class, advanced heart health features developed by ATCOR, a subsidiary of the Company. Pursuant to announcing their new commercial partnership in September 2020, the two companies have been working closely to develop a new consumer smartwatch under the Mobvoi brand with the Company’s proprietary Arty® Heart Health analytics platform, which is an advanced heart and arterial health management ecosystem that leverages the Company’s FDA-cleared gold standard SphygmoCor® technology for measuring central arterial pressure waveforms.

From the CardieX quarterly.

Mobvoi Smartwatch Update

Pre-launch activities ramped up during the quarter in collaboration with Mobvoi. We have built a pipeline of dozens of key influencers/opinion leaders (KOLs) and global technology media journalists as part of our pre and post-launch marketing and media strategy which is currently under embargo. In addition, customer support systems have been established, product inventory is being built up and final pre-launch testing is underway.

Commercial launch is expected within the current March 2022 quarter, and launch announcement will be made shortly before launch dates in the US and Australia/New Zealand, to be advised by Mobvoi.

And we have seen code from the Mobvoi/Ticwatch operating system that includes juicy tidbits.

....................

so after 2.5 years we have this ...

BREAKING NEWS: 9.00am EST, 1 March, 2022 we are officially launching a new era in managing heart and arterial health through our partnership withGooglebackedMobvoiin the launch of a revolutionary new smartwatch featuring our "Arty Heart Health" platform - combined with new, high fidelity, sensor technology. We are introducing multiple "never before seen" clinical health parameters in a wearable device that have traditionally only been available to our research, Pharma, and specialist clinician partners. Medical grade health parameters providing deep insights into your health. It's been a two year collaboration that is finally here

It's time to get excited !

Expand

Come back mate, your contributions here are more appreciated than you realise.
Cheers dig